A disruptive technology that saves lives and improves patient care Main menu Marx Biotechnology is developing a proprietary first-in-class molecular diagnostic kit for the early detection of Graft versus Host Disease (GVHD). GVHD is a life threatening complication of allogeneic (non-self) stem cell transplantation such as bone marrow, peripheral blood or cord blood transplantation

and solid organ transplantations. The cells from the donor react

adversely to the cells in the patient. GVHD affects approximately 50% of all such transplant patients, frequently resulting in death. https://www.youtube.com/watch?v=c_8PcfZSkrI Marx Bios approach has 5 clear advantages:

Incorporated in Jerusalem in January 2011, the Marx Bio team has completed proof of concept in animal studies, has published in a peer reviewed journal, and has filed three patents. It is commencing a Phase 1 clinical trial in humans in Tel Aviv.

Marx Bio has a clear work schedule to deliver a validated and cleared product, ready for market entry within 36 to 48 months. The company is looking for strategic partners to join in that journey.

See the article here:
Marx Biotechnology A disruptive technology that saves ...